

## REVOCATION AND APPOINTMENT OF POWER OR ATTORNEY


DOR BioPharma, Inc., owners of the below-identified applications, appoint as their attorneys and/or agents, with full power of substitution and revocation, to prosecute these applications and transact all business in the United States Patent and Trademark Office, all of the registered practitioners identified by Customer Number 32301:

CATALYST LAW GROUP, APC  
9710 Scranton Rd.  
Suite 170  
San Diego, CA 92121

In regard to the following applications:

Serial/Patent No.	Title	Filed/Issued	Status	Attorney Docket No.
6,096,731	Method for Preventing Tissue Damage Associated with Graft-Host or Host-versus-Graft Disease Following Transplantation	August 1, 2000	Issued	8105-006-US-CIP
10/296,073	Method for Preventing Tissue Damage Associated with Graft-versus-Host or Host-versus-Graft disease following Transplantation	November 22, 2002	Pending	8105-008-WO-US
10/613,788	Method of Long-Term Treatment of Graft-versus-Host Disease Using Topical Active Corticosteroids	July 7, 2003	Pending	8105-009-US-CON
10/098,968	Method of Treating Inflammatory Disorders of the Gastro Intestinal Tract Using Topical Active Corticosteroids	March 15, 2002	Pending	8105-010-US
09/928,890	Method of Treatment of Cancer by Controlling Graft-versus-Leukemia	August 13, 2001	Pending	8105-011-US
09/433,418	Topical Azathioprine for the Treatment of Oral Autoimmune Diseases	November 4, 1999	Pending	8105-013-US

DOR BioPharma, Inc.



DATE: April 17, 2006

Name: Robert N. Brey, Ph.D.  
Title: Chief Scientific Officer